首页 | 本学科首页   官方微博 | 高级检索  
检索        

各国生物类似药沟通交流机制及生物类似药可互换性对比研究及建议
引用本文:张彦彦,王晓东,沈梦娟,杨建红.各国生物类似药沟通交流机制及生物类似药可互换性对比研究及建议[J].现代药物与临床,2019,34(4):916-920.
作者姓名:张彦彦  王晓东  沈梦娟  杨建红
作者单位:沈阳药科大学 亦弘商学院,北京,100027;辉瑞投资有限公司,北京,100000;郑州大学 药物研究院,河南 郑州,450001
摘    要:药品注册中的沟通交流对于控制风险、提高研发注册效率具有重要作用。对美国、欧盟、日本、韩国等国家生物类似药沟通交流机制进行对比研究,结合我国沟通交流的现状,问卷调研和专家研讨,提出完善我国生物类似药沟通交流机制的建议。各国对生物类似药的"可互换性"有着不同的界定和管理。对美欧等国家生物类似药的"可互换性"进行研究,结合问卷调研和专家研讨,提出完善我国生物类似药可互换性的建议。

关 键 词:生物类似药  沟通交流机制  生物类似药的"可互换"  比对研究  问卷调研  建议
收稿时间:2019/3/7 0:00:00

Comparative study on the communication mechanism and interchangeability of biosimilar drugs in different countries and recommendation on improvement for China
ZHANG Yan-yan,WANG Xiao-dong,SHEN Meng-juan and YANG Jian-hong.Comparative study on the communication mechanism and interchangeability of biosimilar drugs in different countries and recommendation on improvement for China[J].Drugs & Clinic,2019,34(4):916-920.
Authors:ZHANG Yan-yan  WANG Xiao-dong  SHEN Meng-juan and YANG Jian-hong
Institution:School of Yeehong Business, Shenyang Pharmaceutical University, Beijing 100027, China,Pfizer, Beijing 100000, China,Institute of Drug Discovery & amp;Development, Zhengzhou University, Zhengzhou 450001, China and School of Yeehong Business, Shenyang Pharmaceutical University, Beijing 100027, China
Abstract:Communication in drug registration plays an important role in controlling risks and improving the efficiency of R&D registration. This paper makes a comparative study on the communication mechanism of biosimilar drugs in the United States, Europe, Japan, South Korea, and other countries, and puts forward suggestions on improving the communication mechanism of biosimilar drugs in China based on the current situation of communication in China, questionnaire survey and expert discussion. Different countries have different definitions and regulations on "interchangeable" biosimilar drugs. In this paper, the "interchangeability" of biosimilar drugs in the United States and Europe, and other countries is studied, combined with questionnaire survey and expert discussion, and suggestions for improving the interchangeability of biosimilar drugs in China are put forward.
Keywords:bio-similar drugs  communication mechanism  interchangeable bio-similar drugs  comparative study  questionnaire survey  recommendation
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号